Keros Therapeutics

Company snapshot

K2B Therapeutics is developing protein-drug/siRNA conjugates with the potential for tumor-agnostic treatment of cancer. Our team believes that K2B's conjugates will revolutionize cancer therapeutics to address significant unmet need. The foundational technology was developed at KIST (Korea Institute of Science and Technology).

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Keros Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Keros Therapeutics.

1. Jun 5, 2026 Clinical update

   Placebo for KER-012, cibotercept — Phase 2

2. Jun 5, 2026 Clinical update

   Dose A KER-012 — Phase 2

3. May 23, 2026 Clinical update

   KER-047 — Phase 2

4. Sep 2, 2025 Patent grant

   GDNF fusion polypeptides and methods of use thereof

5. Jul 22, 2025 Patent grant

   Activin receptor type IIA variants and methods of use thereof

View all clinical trial activity →

• What is Keros Therapeutics?

  K2B Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker KROS. Primary therapeutic focus areas include Pulmonary Arterial Hypertension, Iron Deficiency Anemia. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 12 p

• Is Keros Therapeutics publicly traded?

  Yes. Keros Therapeutics is listed with ticker KROS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Keros Therapeutics develop or market?

  We link 2 drug profile(s) where Keros Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/keros-therapeutics#company-drugs.

• What are the latest developments for Keros Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 4 US patent grant(s) tied to this profile.

• What therapeutic areas does Keros Therapeutics focus on?

  Keros Therapeutics focuses on Pulmonary Arterial Hypertension, Iron Deficiency Anemia based on our analysis of their pipeline programs and drug development activities.